COVID-19: Ono Pharmaceutical’s “Foipan” Appears: New Corona Phase I Clinical Trial
COVID-19:
Ono Pharmaceutical:
On June 5, the company announced that it has started Phase I clinical trial (P1) to convert the Ono drug/chronic pancreatitis drug “Foipan” into a COVID-19 drug.
Results are expected in August 2020.
Based on the results, we proceed to clinical trials for patients with new coronavirus infection.
What is “Foipan”:
Foipan is a remedy for chronic pancreatitis.
Several research groups, including the University of Tokyo, have reported their usefulness for new coronavirus infections.
Mechanism of action:
It inhibits the fusion between the viral outer membrane and the human cell membrane that occurs during infection.
Chemical Daily
https://www.chemicaldaily.co.jp/
Foipan Tablets, a protease inhibitor, begins clinical trials for new coronavirus infection (COVID-19)
https://www.ono.co.jp/jpnw/PDF/n20_0605_3.pdf
Basic information of Foipan Tablets 100mg (actions/side effects/drinking/package insert) [QLife drug search]
https://www.qlife.jp/meds/rx10400.html
The University of Tokyo: Clinical study on new model coronastat
Cell Paper:
When a new coronavirus infects human cells,
After binding to the “receptor protein called ACE2 on the cell membrane”,
Utilizing “enzyme called TM serine protease on cell membrane/TMPRSS2“,
It has been reported to invade cells.
Camostat:
It is known to have a function to prevent TMPRSS2.
Severe respiratory syndrome (SARS)
For Middle East respiratory syndrome (MERS)
“Preventing the causative infection of coronaviruses” has been previously reported at the laboratory level.
This paper:
Camostat reports that the novel coronavirus and SARS virus prevent infection of human cells.
What is a camostat:
“Drugs that act to interfere with the action of proteolytic enzymes”
Ono Pharmaceutical:
Created by Ono Yakuhin Kogyo Co., Ltd. and released in 1985 under the name “Foipan Tablets”.
The substance patent has already expired, and many generic drug manufacturers are selling drugs with the same ingredients in Japan.
: Nikkei Biotech ONLINE